Results 71 to 80 of about 297 (139)
Computational modeling approaches for circulating cellfree DNA in oncology
International audienceMany cancer patients undergoing immune-checkpoint inhibition (ICI) experience early progression (EP), defined as progression at the first imaging evaluation.
Nguyen Phuong, Linh
core +3 more sources
International audienceBackground: Immune-checkpoint inhibition (ICI) has significantly advanced cancer treatment, but many patients experience early progression (EP).
Boutonnet, Audrey +9 more
core +1 more source
Seminal plasma cfDNA fragmentomics landscape delineates male infertility subtypes
Abstract Background While cell-free DNA (cfDNA) fragmentomics has transformed liquid biopsy applications in prenatal screening and oncology, its potential in male reproductive health remains uncharted. Methods Through integrated whole-genome sequencing and jagged end sequencing (Jag-Seq) coupled with non-CpG methylation analysis, we ...
Wu, Xiaoyu +4 more
openaire +2 more sources
Innovations in Early Lung Cancer Detection: Tracing the Evolution and Advancements in Screening
Lung cancer mortality rates, particularly non-small cell lung cancer (NSCLC), continue to present a significant global health challenge, and the adoption of lung cancer screening remains limited, often influenced by inequities in access to healthcare ...
Demetria Tennefoss +7 more
core +1 more source
DeepFRAG: a method for cancer detection based on DNA fragmentomics and deep learning
Abstract Motivation Cancer screening using liquid biopsy technology has become standard in modern clinical and preventive oncology. This method analyzes cell-free DNA (cfDNA) circulating in a patient’s bloodstream.
Andrey Koch, Eldar Giladi
openaire +3 more sources
International audienceEarly prediction of resistance to immunotherapy is a major challenge in oncology. The ongoing SChISM (Size Cell-fre DNA (cfDNA) Immunotherapies Signature Monitoring) clinical study proposes an innovative approach based on patented ...
Boutonnet, Audrey +11 more
core +1 more source

